{{Rsnum
|rsid=460106
|Gene=HIC2
|Chromosome=22
|position=21452112
|Orientation=plus
|GMAF=0.4555
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 61.9 | 31.0 | 7.1
| HCB | 22.6 | 52.6 | 24.8
| JPT | 28.3 | 54.0 | 17.7
| YRI | 14.4 | 41.1 | 44.5
| ASW | 16.1 | 48.2 | 35.7
| CHB | 22.6 | 52.6 | 24.8
| CHD | 24.8 | 44.0 | 31.2
| GIH | 27.0 | 54.0 | 19.0
| LWK | 7.3 | 43.6 | 49.1
| MEX | 15.8 | 47.4 | 36.8
| MKK | 9.0 | 43.6 | 47.4
| TSI | 48.0 | 44.1 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs460106
|Name_s=
|Gene_s=HIC2
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.40, combined P value= 5.62E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470245
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs460106
|overall_frequency_n=75
|overall_frequency_d=128
|overall_frequency=0.585938
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=62
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}